upper GI bleeding
Resuscitate first, endoscope within 24 h. Glasgow-Blatchford ≤1 → outpatient. Restrictive transfusion (Hb <70–80 g/L; higher with cardiovascular disease). Erythromycin before endoscopy; IV PPI optional while waiting; no tranexamic acid. Treat high-risk stigmata (Forrest Ia/Ib/IIa) endoscopically → 72 h high-dose PPI → BID to day 14. Continue ASA for secondary prevention; don’t reverse warfarin or DOACs routinely. Suspected cirrhosis → treat as variceal until proven otherwise (variceal bleeding).
UGIB admission bundle
- 2 large-bore IVs; group & screen/crossmatch; CBC, INR, urea, creatinine, LFTs, lactate
- Glasgow-Blatchford score; ≤1 and stable → outpatient endoscopy
- transfuse Hb <70–80 g/L (≥80 if active cardiovascular disease); not to a “normal” Hb
- high-dose IV PPI now — don’t delay endoscopy for it
- erythromycin 250 mg IV 20–90 min before endoscopy
- NPO; GI consult → endoscopy within 24 h of presentation
- cardiac ASA for secondary prevention → continue; primary prevention → stop
- warfarin/DOAC → hold; reverse only if life-threatening → anticoagulant reversal
- if cirrhosis or suspected varices: octreotide + ceftriaxone, see variceal bleeding
- no tranexamic acid
- post-endoscopy high-risk stigmata → PPI 80 mg bolus + 8 mg/h × 72 h (ACG 2021 also accepts 40 mg BID–QID)
- ulcer → H. pylori test; repeat if negative during the bleed
- unstable despite resuscitation → ICU, airway before endoscopy if haematemesis + ↓LOC
risk stratification and resuscitation
Glasgow-Blatchford score (GBS) — pre-endoscopy, uses urea, Hb, SBP, HR, melaena, syncope, liver disease, heart failure. GBS 0–1 → ≤1% need intervention or die → discharge with outpatient endoscopy. GBS beats AIMS65 and pre-endoscopic Rockall for this purpose; neither is recommended for safe discharge.
Transfusion — restrictive strategy lowers mortality and rebleeding (Villanueva, NEJM 2013: threshold 70 vs 90 g/L; excluded massive exsanguination and cardiovascular disease).
- No cardiovascular disease: transfuse <80 g/L (CAG-endorsed International Consensus); ACG uses 70 g/L. Either is defensible; 80 g/L leaves margin for the equilibration lag.
- Cardiovascular disease: higher threshold (no agreed number; ≥80 g/L).
- Exsanguinating bleed: thresholds don’t apply — massive transfusion protocol.
Urea:creatinine ratio — raised urea out of proportion to creatinine points to an upper source (digested blood + volume depletion).
before endoscopy
- PPI — high-dose IV PPI downstages stigmata and reduces need for endoscopic therapy; no effect on rebleeding, surgery or mortality. Reasonable while waiting, never a reason to delay the scope. Give it even if varices are suspected — the source is unknown until the scope.
- Erythromycin 250 mg IV 20–90 min before endoscopy — prokinetic clears clot from the stomach → better views, fewer repeat scopes. Check QTc.
- No tranexamic acid — HALT-IT (2020) (n=12 009): no mortality benefit, more venous thromboembolism and seizures.
- Octreotide/somatostatin — no role in nonvariceal bleeding; only if varices suspected.
- NG tube — optional; aspirate may help prognosis but doesn’t change management.
timing of endoscopy
Within 24 h of presentation for anyone admitted. Earlier is not better in stable high-risk patients: Lau, NEJM 2020 — GBS ≥12, endoscopy within 6 h vs 6–24 h, no difference in 30-day mortality or rebleeding. Haemodynamic instability despite resuscitation → urgent endoscopy once resuscitated (intubate first if airway at risk).
endoscopic findings and post-endoscopy care
| Forrest | lesion | rebleed risk untreated | endoscopic therapy |
|---|---|---|---|
| Ia / Ib | spurting / oozing | high | yes |
| IIa | non-bleeding visible vessel | high | yes |
| IIb | adherent clot | intermediate | irrigate to dislodge; treat underlying lesion; PPI alone acceptable |
| IIc / III | flat pigmented spot / clean base | low | no — discharge early, oral PPI, feed |
Endoscopic therapy: thermal coagulation, clips or sclerosant; epinephrine only in combination. Haemostatic powder (TC-325) as temporising rescue.
After haemostasis of high-risk stigmata:
- PPI: 80 mg IV bolus + 8 mg/h × 72 h, or intermittent 40 mg IV/PO BID–QID × 72 h (ACG 2021: equivalent; the International Consensus endorses only the infusion)
- then PPI BID until day 14, then once daily for a duration set by the cause
- stay in hospital ≥72 h — most rebleeding happens in this window
- no routine second-look endoscopy
Rebleeding → repeat endoscopy and endoscopic therapy → if that fails, transcatheter arterial embolisation → surgery.
Ulcer → test for H. pylori and treat (peptic ulcer disease and H. pylori). A negative biopsy-based test during the bleed (PPI, blood in the stomach) → repeat later. Confirm eradication.
antithrombotics during the bleed
Continue cardiac ASA through the bleed; if it was held, restart the day haemostasis is confirmed endoscopically. Stopping it raises cardiovascular events and mortality more than it lowers rebleeding. ASA for primary prevention isn’t covered by this guidance — after a GI bleed it’s generally stopped (ACG 2023 suggests stopping after diverticular bleeds).
| drug | during acute GI bleed (ACG-CAG 2022) |
|---|---|
| warfarin | hold; against vitamin K and FFP; PCC preferred over FFP only if reversal needed (life-threatening bleed, INR well above range, or massive transfusion undesirable) |
| DOACs | hold; against routine PCC, idarucizumab or andexanet — short half-life does the work. Consider specific reversal only if life-threatening and dose within 24 h |
| antiplatelet | against platelet transfusion |
| DAPT | keep ASA; P2Y12 inhibitor decision with cardiology (recent stent → stent thrombosis risk) |
Applies to upper and lower GI bleeding. Endoscopy is not delayed for anticoagulation. Life-threatening = shock or hypotension needing pressors or surgery, Hb drop >50 g/L, or ≥5 units RBC. Reversal agents and doses → anticoagulant reversal.
Restarting anticoagulation — resume once bleeding has stopped: resumption lowers thromboembolism and mortality (ACG 2023 LGIB, strong). No trial defines the exact day; balance thrombotic indication against rebleed risk.
secondary prevention
- NSAIDs, antiplatelets or anticoagulants after an ulcer bleed (COX-2 + PPI, long-term PPI, pantoprazole with clopidogrel) → peptic ulcer disease and H. pylori.
- Iron deficiency after the bleed → iron deficiency.
key points
- Cirrhosis + GI bleed → ceftriaxone and octreotide before endoscopy regardless of the presumed source (variceal bleeding).
- Melaena with a negative upper endoscopy and colonoscopy → small-bowel source (lower GI bleeding).
Prepared 2026-10-28. Not yet verified — check every number against the sources.